Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SKL, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group. Chan A, et al. Among authors: harker g. Lancet Oncol. 2016 Mar;17(3):367-377. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10. Lancet Oncol. 2016. PMID: 26874901 Clinical Trial.
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Kim SB, Jakobsen EH, Harvey V, Robert N, Smith J 2nd, Harker G, Zhang B, Eli LD, Ye Y, Lalani AS, Buyse M, Chan A. Chia SKL, et al. Among authors: harker g. Breast Cancer Res. 2019 Mar 11;21(1):39. doi: 10.1186/s13058-019-1115-2. Breast Cancer Res. 2019. PMID: 30867034 Free PMC article. Clinical Trial.
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg LJ, Obasaju C, Orlando M, Yardley DA. Borson R, et al. Among authors: harker g. Clin Breast Cancer. 2012 Oct;12(5):322-30. doi: 10.1016/j.clbc.2012.07.004. Clin Breast Cancer. 2012. PMID: 23040000 Clinical Trial.
Prognostic indicators in head and neck cancer patients receiving combined therapy.
Davis RK, Stoker K, Harker G, Davis K, Gibbs FA Jr, Harnsberger HR, Stevens MH, Parkin JL, Johnson LP. Davis RK, et al. Among authors: harker g. Arch Otolaryngol Head Neck Surg. 1989 Dec;115(12):1443-6. doi: 10.1001/archotol.1989.01860360045015. Arch Otolaryngol Head Neck Surg. 1989. PMID: 2573381
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM. Hesketh PJ, et al. Among authors: harker g. J Clin Oncol. 1997 Jan;15(1):103-9. doi: 10.1200/JCO.1997.15.1.103. J Clin Oncol. 1997. PMID: 8996130 Review.
Thermochemotherapy in inoperable head and neck cancer.
Davis RK, Gibbs FA, Sapozink MD, Farver M, Harker G. Davis RK, et al. Among authors: harker g. Otolaryngol Head Neck Surg. 1990 Dec;103(6):897-901. doi: 10.1177/019459989010300602. Otolaryngol Head Neck Surg. 1990. PMID: 2126122
76 results